AG490 suppresses interleukin‐34‐mediated osteoclastogenesis in mice bone marrow macrophages

Interleukin‐34 (IL‐34) has been recently identified as a novel cytokine, substituting for the function of macrophage colony‐stimulating factor (M‐CSF), a pivotal osteoclastogenic factor involved in bone‐related diseases (e.g., osteomyelitis of the jaws). However, the molecular mechanisms are not ful...

Full description

Saved in:
Bibliographic Details
Published inCell biology international Vol. 41; no. 6; pp. 659 - 668
Main Authors Cheng, Xin, Wan, Qi‐Long, Li, Zu‐Bing
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Interleukin‐34 (IL‐34) has been recently identified as a novel cytokine, substituting for the function of macrophage colony‐stimulating factor (M‐CSF), a pivotal osteoclastogenic factor involved in bone‐related diseases (e.g., osteomyelitis of the jaws). However, the molecular mechanisms are not fully understood. This study aimed to explore the potential mechanism of IL‐34 in receptor activator of NF‐kB ligand (RANKL)‐induced osteoclast formation. We found that IL‐34 alone significantly maintained the survival of bone marrow macrophages (BMMs) and enhanced the expression of the osteoclast‐related genes TRAP, Ctsk, and NFATc1, as well as TRAP‐positive multinucleated cells combined with RANKL, which can be reversed by AG490. Conversely, AG490 did not affect the M‐CSF‐mediated osteoclastogenesis in the presence of RANKL. The protein expression of p‐STAT3 in BMMs was enhanced by IL‐34 combined with RANKL compared with RANKL alone, and AG490 inhibited the expression of p‐SATA3 at protein level in the IL‐34 plus RANKL group, resulting in significantly increased Smad7 expression. This study demonstrated for the first time that IL‐34 may play a crucial role in RANKL‐induced osteoclastogenesis by promoting the proliferation and differentiation of BMMs, stimulating p‐STAT3 expression, and inhibiting the expression of Smad7 in the absence of M‐CSF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1065-6995
1095-8355
DOI:10.1002/cbin.10771